44.JPG)
The Artificial Intelligence in Epidemiology Market Size is valued at 475.63 Million in 2024 and is predicted to reach 5271.80 Million by the year 2034 at an 27.4% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
Artificial intelligence (AI) is an intelligent system that performs various human intelligence-based operations in domains such as biology, computer science, mathematics, linguistics, psychology, and engineering. These talents include reasoning, learning, and problem-solving. In the healthcare industry, artificial intelligence is used to analyze complex medical data using algorithms and software. Rising public awareness of the significance of technology in chronic disease diagnosis and monitoring will be a significant driving force in the progress of AI applications in epidemiology. As healthcare research and development efforts expand, so will the demand for artificial intelligence in epidemiology labs.
The extensive usage and use of AI in drug research and discovery activities is a critical motivator. Pharmaceutical and biotech companies have also increased their R&D investments. This investment interest is driving the adoption of AI systems to follow the progression of syndromic diseases. The growing burden of chronic diseases has increased the need for effective control measures and the development of feasible treatment solutions. Government-backed programs, more significant investment from private investors and venture capitalists, and the creation of AI-focused start-ups worldwide are driving market expansion. Despite the prevalence of the diseases, the high cost of these techniques may impede the growth of the worldwide AI-based critical care market.
Artificial intelligence in the epidemiology market is segmented on the deployment, applications and end users. Based on deployment, the market is segmented into web-based and cloud-based. Based on application, artificial intelligence in the epidemiology market is segmented into infection prediction & forecasting and disease & syndromic surveillance. Based on the end user, artificial intelligence in the epidemiology market is segmented into government & state agencies, research labs, pharmaceutical & biotechnology companies, and healthcare providers.
The market's leading segment is healthcare providers. As a result of recent increases in awareness and correction of some common misconceptions about the intake of certain veggies, consumer acceptance and widespread application for equestrian and cow feeding are expected to drive demand for GMO veggies, strengthening segmental development.
Web-based grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the expected time. Adopting web-based software in epidemiology provides various advantages, including the possibility of integrating with other interoperable platforms. Web-based resources are also being developed to give health information and aid decision-making quickly. Such advancements will accelerate the use of AI in web-based epidemiological data analysis.
The North American artificial intelligence in epidemiology market is expected to register the highest market share in revenue shortly. Because of developments in healthcare IT infrastructure, rising healthcare expenditures, widespread technology use, favourable government efforts, and the presence of numerous key market competitors, The region has seen an increase in the use of AI technologies by federal authorities. The presence of key technology players will also facilitate the efficient integration of AI in epidemiology. Countries such as the United States and Canada are home to big pharmaceutical and biotechnology corporations that invest heavily in research, indicating a promising future for North American AI solution suppliers. Besides, Asia-Pacific is predicted to increase due to significant breakthroughs and development in IT infrastructure and entrepreneurial initiatives specialized in AI-based technologies. Artificial intelligence (AI) is an intelligent system that performs various functions.
|
Report Attribute |
Specifications |
|
Market size value in 2024 |
USD 475.63 Million |
|
Revenue forecast in 2034 |
USD 5271.80 Million |
|
Growth rate CAGR |
CAGR of 27.4% from 2025 to 2034 |
|
Quantitative units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
Deployment, Application, End-Use |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;France; Italy; Spain; Japan; South Korea; South East Asia |
|
Competitive Landscape |
Cognizant Technology Solutions Corporation, Cerner Corporation (Oracle), Epic Systems Corporation, eClinicalWorks LLC, Alphabet Inc., Komodo Health, Microsoft Corporation, Meditech, Predixion Software, Siemens Healthineers AG, Intel Corporation, Bayer Healthcare, Artificial Intelligence for Medical Epidemiology (AIME), Cardiolyse, and SAS Institute, Inc |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
By Deployment
By Application
By End-use
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
